We have demonstrated the effects of estrogen on modulation of ATP-sensitive K ϩ channels; however, the subcellular location of these channels is unknown. The purpose of the present study was to investigate the role of the sarcolemmal and mitochondrial ATP-sensitive K ϩ channels in a canine model of myocardial infarction after stimulation with 17␤-estradiol. Anesthetized dogs were subjected to 60 min of the left anterior descending coronary artery occlusion followed by 3 h of reperfusion. Infarct size was markedly reduced in estradiol-treated dogs compared with controls (14 Ϯ 6 versus 42 Ϯ 6%, P Ͻ 0.0001), indicating the effective dose of estradiol administrated. Pretreatment with the mitochondrial ATP-sensitive K ϩ channel antagonist 5-hydroxydecanoate completely abolished estradiol-induced cardioprotection. The sarcolemmal ATP-sensitive K ϩ channel antagonist 1-15-12-(5-chloro-o-anisamido)ethylmethoxyphenyl)sulfonyl-3-methylthiourea (HMR 1098) did not significantly attenuate estradiol-induced infarct size limitation.
In addition, estradiol administration significantly reduced the incidence and duration of reperfusion-induced ventricular tachycardia and ventricular fibrillation. Although 5-hydroxydecanoate alone caused no significant effect on the incidence of reperfusion arrhythmias in the presence or absence of estradiol, the administration of HMR 1098 abolished estrogen-induced improvement of reperfusion arrhythmias. Pretreatment with the estrogen-receptor antagonist faslodex (ICI 182, 780) did not alter estrogen-induced infarct-limiting and antiarrhythmic effects. These results demonstrate that estrogen is cardioprotective against infarct sizes and fatal reperfusion arrhythmias by different ATP-sensitive K ϩ channels for an estrogen receptor-independent mechanism. The infarct size-limiting and antiarrhythmic effects of estrogen were abolished by 5-hydroxydecanoate and HMR 1098, suggesting that the effects may result from activation of the mitochondrial and sarcolemmal ATP-sensitive K ϩ channels, respectively.
Epidemiological studies showed that women appear to have a lower incidence of arrhythmia-related sudden death than men (Sourander et al., 1998) . Estrogen can decrease cardiovascular mortality primarily in sudden cardiac death in postmenopausal women (Sourander et al., 1998) . However, the mechanism involved is not completely known. Fatal reperfusion arrhythmia occurring in the absence of heart failure or hypotension is a common complication of acute myocardial infarction (Volpi et al., 1987) . Estrogen has been shown previously to attenuate reperfusion-induced ventricular arrhythmias in the dog (McHugh et al., 1995) . The antiarrhythmic effects of estrogen have been attributed to antioxidants (McHugh et al., 1998) , resulting in a reduction of free radicals during reperfusion. We have previously demonstrated that there is an association of estrogen and ATPsensitive K ϩ channels in patients with syndrome X by analyzing the changes of electrocardiographic QT parameters (Lee et al., 1999) . However, no previous study has addressed this issue on the effects of estrogen on ATP-sensitive K ϩ channels and the incidence of arrhythmias during myocardial reperfusion.
Cardioprotection via ATP-sensitive K ϩ channels may be an integral player in ischemic preconditioning (IP), where brief periods of ischemia and reperfusion before a sustained ischemic stress protects the heart. We have previously demonstrated that estrogen can activate mitochondrial ATP-sensitive K ϩ (mit-K ATP ) channels and mimicked IP to reduce myocardial infarct size in anesthetized dogs (Lee et al., 2000) . Cardiac myocytes contain two distinct ATP-sensitive K ϩ channels with one subtype located in the sarcolemma (sar-K ATP ) and the other in the inner membrane of the mitochondria (mit-K ATP ) (Liu et al., 2001) . mit-K ATP channels share some pharmacological properties with sar-K ATP channels while possessing a distinct pharmacological response. sar-K ATP channels are selectively blocked by HMR 1098, whereas mit-K ATP channels are specifically inhibited by 5-hydroxydecanoate (Liu et al., 2001) . The involvement of the two types of ATP-sensitive K ϩ channels in estradiol-induced infarct size and antiarrhythmias during ischemic and reperfusion remained unknown. Although there is an emerging consensus that the activation of mit-K ATP channels reduces infarct size, there are widely divergent views regarding whether sar-K ATP channels act in an antiarrhythmic role during reperfusion. Activation of sar-K ATP channels can theoretically be antiarrhythmic, because shortening of the action potential duration by opening these channels would suppress triggered activity, which is an important mechanism of reperfusion arrhythmias (Wilde and Janse, 1994) . However, several studies have demonstrated a decrease in arrhythmic severity with ATP-sensitive K ϩ channel blockers (Dhein et al., 2000) . This discrepancy may stem from different species (dogs, pigs, rabbits, rats), collateral flow measurements (microspheres versus others), model studies (isolated heart versus in vivo), and different arrhythmic quantitative methods (arrhythmic score versus incidence) used in the studies. Small animals did not provide a good model to assess the pharmacological effects on arrhythmias because their hearts are too small to sustain arrhythmias (Sakamoto et al., 1999) . Such tests are performed better in large animals. Thus, this study investigated whether pretreatment with 17␤-estradiol in physiological concentrations provides cardioprotection against infarct size and fatal reperfusion arrhythmias in a canine model of acute myocardial infarction. We have also investigated whether the observed antinecrotic and antiarrhythmic effects of 17␤-estradiol are due to the activation of mit-and sar-K ATP channels by the use of 5-hydroxydecanoate and HMR 1098, specific mit-and sar-K ATP channel blockers, respectively. Besides, to assess whether the estrogen-induced effects are related to activation of estrogen receptors, we used a specific estrogen receptor antagonist ICI 182,780.
Materials and Methods

Preparation
All experiments were conducted on male mongrel dogs, weighing 10 to 15 kg. Because we have previously demonstrated that estrogen provided the similar magnitude of cardioprotection in both sexes of canine hearts (Lee et al., 2000) , we used male animals in this study. The experimental preparation and techniques have been previously described (Lee et al., 2000) . Pentobarbital-anesthetized dogs were instrumented. Fluid replacement, plasma [K ϩ ] and [Ca 2ϩ ], and basic physiological conditions were controlled as described (Lee et al., 2000) .
Near the base of the heart, the left anterior descending artery proximal to the first diagonal branch was encircled with a 4-0 silk suture. Because the degree of preceding ischemia is one determinant of the severity of infarct size and reperfusion arrhythmias (Jugdutt et al., 1981) , we intended to produce similar ischemia by monitoring collateral blood flow at baseline and during ischemia. Collateral coronary blood flow was detected by intracoronary Doppler flow wire as previously described (Lee et al., 2000) . All procedures were in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication 85-23, revised 1996) and approved by the Animal Subjects Committee of National Taiwan University.
Experimental Protocol
Protocol 1 (n ‫؍‬ 95). The dogs were randomized to one of six groups (Fig. 1) . All animals were subjected to a 60-min coronary occlusion followed by 180 min of reperfusion. The doses of estradiol were chosen to achieve serum levels in the range of 200 to 500 pg/ml, levels equivalent to those in human females during midcycle. The dose of 5-hydroxydecanoate (5 mg/kg, serum level around 100 M when extracellular space is assumed to be 20% of body weight) was used to selectively block mit-K ATP channels and to avoid to affect sar-K ATP channels, which are insensitive to 500 M of 5-hydroxydecanoate (Hu et al., 1999) . 5-Hydroxydecanoate was administered 5 min before prolonged coronary occlusion, which has been shown to be maximally effective in inhibiting cardioprotection (Fryer et al., 2000) . HMR 1098 was administered at the dose of 3 mg/kg, which was an optimal dosage to determine the effectiveness of inhibiting the sar-K ATP channels in IP (Fryer et al., 2000) .
Protocol 2 (n ‫؍‬ 45). To assess whether the estradiol-induced effects were of nongenomic origin, we performed another four groups randomly allocated to either placebo or estrogen administration in the presence or absence of intravenous infusion of ICI 182,780 at a dose of 2.5 mg/kg, a classical estrogen receptor antagonist, 5 min before a 60-min coronary occlusion. The dosage administered was chosen on the basis of data from previous studies (Robertson et al., 2001) , suggesting that the dose of ICI 182,780 is sufficient to block estrogen receptors.
Measurements of Infarct Size
Infarct size was determined as previously described (Lee et al., 2000) using 1% triphenyltetrazolium chloride (Sigma, St. Louis, MO) in phosphate buffer (pH 7.4). Left ventricular area at risk and the area of infarcted tissue were measured by an independent, blinded observer using computer planimetry.
To verify the reproducibility of the computer-assisted planimetry, Fig. 1 . Protocol bars indicate experiments used to study effects of various interventions in a canine ischemia/reperfusion model. Group I was the control group, and only vehicle (1.0 ml of ethanol) was administered before the 60-min occlusion. In Group II (17␤-estradiol, E2), animals were treated with intravenous 10 g/kg E2 15 min before the 60-min occlusion. In Group III (5-hydroxydecanoate, 5-HD), intraventricular 5-HD (5 mg/ kg, Research Biochemical International, Natick, MA) was given 5 min before the 60-min occlusion. In Group IV (HMR 1098), intravenous HMR 1098 (3 mg/kg, a generous gift from Aventis Pharmaceuticals [Strasbourg, France]) was given 15 min before the 60-min occlusion. In Groups V to VI, dogs received E2 combined with either 5-HD or HMR 1098. OCC, occlusion; REP, reperfusion.
a second measurement was performed by another, blinded investigator. The correlation between the two measurements was excellent (r ϭ 0.992 for ischemic area).
Arrhythmia Analysis
The acquired single-lead electrocardiographic tracing was continuously displayed. All arrhythmic events were classified by the observer according to the guidelines provided by "the Lambeth conventions" (Walker et al., 1988) . Ventricular tachycardia (VT) was defined as less than or equal to four consecutive ventricular premature beats. Ventricular fibrillation (VF) was defined as a signal that changed from beat to beat in rate and configuration (Fig. 2) . Reference was made to the blood pressure signal to confirm which type of ectopic activity was occurring, particularly to distinguish between polymorphic VT and VF. When the former occurs, the pressure trace is usually still pulsatile, whereas with VF the blood pressure falls rapidly toward zero and is no longer pulsatile. The onset, durations, and incidence of VT and VF were measured occurring within the whole reperfusion period. Measurements of all variables were performed in a blinded manner.
Laboratory Measurements
17␤-Estradiol concentrations were quantified by enzyme-linked immunoassay (Diagnostic Products Corporation, Los Angeles, CA) before and at the end of the study. The detection limit was 20 pg/ml for estradiol.
Exclusion Criteria
Animals were omitted from analysis for infarct size: 1) if intractable VF occurred or arrhythmia needed antiarrhythmic agents to correct; 2) if such severe hypotension was observed that the experiment could not be continued successfully for the duration of the protocol; or 3) if heart worms were present. Because of influence of collateral circulation on infarct sizes (Jugdutt et al., 1981) , we excluded collateral flow Ͼ20% of baseline coronary blood flow to make our study animals homogeneous. Dogs with VF during reperfusion were resuscitated and converted to a stable rhythm by internal electric shocks (3 ϫ 10 W). The low energy did not result in more cell necrosis (de Lorgeril et al., 1990) . We calculated survival percentage as (number of dogs that survived)/(number of originally assigned dogs Ϫ number of dogs with heart worms or collaterals Ͼ 20%) ϫ 100.
Statistics
All values are expressed as mean Ϯ S.D. Differences among groups in hemodynamics, coronary blood flow, infarct size, and area at risk were compared using one-way analysis of variance followed by Student-Newman-Keuls test. Differences in the incidence of arrhythmias among the groups were determined by the chi-square test and Fisher's exact test if case number Ͻ 5. Difference in the VT and VF durations among the groups was tested by the Mann-Whitney test because of no Gaussian distribution. A value of P Ͻ 0.05 was considered to be significant.
Results
Intravenous injection of 10 g/kg 17␤-estradiol resulted in increases of plasma estradiol concentration (Table 1) equivalent to those in human females during midcycle. Concentration of arterial blood gas, calcium, sodium, and potassium were fairly stable throughout the study.
Mortality and Exclusions. A total of 95 animals were enrolled in the protocol 1, and 72 successful experiments were completed. Six dogs were excluded because of intractable VF (two in control; one in 5-hydroxydecanoate, HMR 1098, 17␤-estradiol ϩ 5-hydroxydecanoate, and 17␤-estradiol ϩ HMR 1098). Ten dogs were excluded from analysis because collateral circulation exceeded 20% of baseline (two in control, 17␤-estradiol, 5-hydroxydecanoate, and HMR 1098; one in 17␤-estradiol ϩ 5-hydroxydecanoate and 17␤-estradiol ϩ HMR 1098). Six dogs were excluded because of intractable hypotension (two in control and HMR 1098; one in 5-hydroxydecanoate and 17␤-estradiol ϩ HMR 1098). One dog was excluded because of the presence of heart worms (one in 17␤-estradiol). The remaining dogs were randomly assigned to each group of 12.
Hemodynamic Variables. The hemodynamic data are summarized in Table 1 . Heart rate, mean blood pressure, and rate-pressure product were not significantly different among the six groups.
Baseline coronary blood flow measured with intracoronary Doppler flow wire was nonsignificantly different among the six groups (Table 1) . Five minutes after occlusion, collateral blood flow in the center of the ischemic region was very low in the six groups, and increased only slightly with time. Blood flow of the left anterior descending artery among the six groups was similar during coronary occlusion, suggesting that collateral flow to the ischemic region may be not altered by treatment assignment. Coronary blood flow during hyperemic responses and reperfusion was also similar among the six groups.
Infarct Size and Area at Risk. There was no significant difference in area at risk expressed as a percentage of the left ventricle among the groups, indicating a comparable degree of ischemic risk (Fig. 3) . Infarct size in control animals averaged 42 Ϯ 6% of the risk region, compared with 14 Ϯ 6% of the risk region in estrogen-treated dogs (P Ͻ 0.0001), indicating that an effective dose was used in this study. Pretreatment with 5-hydroxydecanoate completely abolished estrogen-pretreatment (14 Ϯ 6 to 38 Ϯ 6% of the risk region, P Ͻ 0.0001) cardioprotection. HMR 1098 did not significantly attenuate infarct size in the presence of estrogen. These data suggest a mit-K ATP channel-sensitive, sar-K ATP channel-in- The selective estrogen receptor antagonist ICI 182,780 did not cause change in either area at risk or infarct size in the absence or presence of 17␤-estradiol, suggesting a nongenomic cardioprotective effect (Table 3) .
Reperfusion Arrhythmias. As summarized in Table 2 , 100% of the control dogs developed reperfusion VT, and 83% of them deteriorated into VF. 17␤-estradiol administration reduced the incidence of VT by 83% and VF by 83%. Duration of VT in the estrogen-treated heart was significantly shorter than in the control (129 Ϯ 45 versus 1054 Ϯ 221 s, P Ͻ 0.0001). Either HMR 1098 or 5-hydroxydecanoate alone did not produce significant increase of fatal reperfusion arrhythmias compared with the control group. However, the antiarrhythmic properties of estradiol were abolished with the use of HMR 1098 in terms of the incidence and duration of VT and the incidence of VF. The reduced reperfusion arrhythmic incidence and durations induced by estrogen was not significantly altered by ICI 182,780 (Table 3) .
Discussion
Our present results clearly showed for the first time that estrogen at physiological doses exerts its beneficial effect on infarct sizes and reperfusion arrhythmias at different subcellular location through a nongenomic mechanism in anesthetized dogs. There is a separate mechanism modulating infarct size and reperfusion arrhythmias. The infarct sizelimiting effect of estrogen was abolished by 5-hydroxydecanoate, suggesting that the cardioprotective effect of estrogen may result from activation of myocardial mit-K ATP channels. Estradiol effectively attenuates the incidence and durations of reperfusion-induced VT and VF. This antiarrhythmic effect was abolished by HMR 1098 at the dose to selectively block sar-K ATP channels, implying that beneficial effects appear to be mediated through the opening of myocardial sar-K ATP channels. Our findings imply an important difference in the mechanism of these two channels on cardioprotection.
Estrogen and ATP-Sensitive K ؉ Channels. The mechanisms by which activation of ATP-sensitive K ϩ channels by estradiol protected the heart against infarct sizes and reperfusion arrhythmias remain to be defined. Clearly, estrogen did not exert any hemodynamic effects and was not associated with an increase in myocardial blood flow at the dose used in this study. Rate pressure product, an index of myocardial oxygen consumption, was similar throughout the study among the groups, indicating that changes in myocardial metabolism cannot be a mechanism for beneficial effect of the drug. The finding was consistent with the result of McHugh et al. (1995) , showing the unchanged hemodynamics throughout ischemia reperfusion in dogs treated with estrogen at a physiological dose. Collateral blood flow during coronary occlusion among the six groups was similar, demonstrating that the differences in infarct sizes and arrhythmic incidence were not explained by collateral blood flow. The lack of effect of ICI 182,780 on infarct-limiting and antiarrhythmic effects of estrogen suggests that these favorable effects of estrogen are direct, nongenomic effects different from the classical intracellular estrogen receptors. The ability of estrogens to target genomic and nongenomic mechanisms leads to activation of signaling pathways, which may occur within minutes or require hours. The mechanisms by which estrogens affect cell function independent of their binding to estrogen receptors are not well understood. Because estrogens are lipophilic, it has been suggested that they could alter the interaction of cell membrane lipids and proteins by changing the structure of sarcolemmal lipid membranes (Russell et al., 2000) . However, whether myocardial response to estrogen can be mediated by estrogen binding to a cell surface form of estrogen receptor remained unknown.
17␤-Estradiol has been shown to activate K ϩ channels in some (Sudhir et al., 1995; Hugel et al., 1999) but not all studies (Nakajima et al., 1999; Tanabe et al., 1999) . The ATP-sensitive K ϩ channel, a member of the superfamily of Kir channels, is a heteromultimer composed of a pore-forming K ϩ channel core and a regulating ATP-binding cassette protein (Jovanovic et al., 1999) . However, a Kir blocker terikalant has no effect on the current of ATP-sensitive K ϩ channel (Escande, 1989) . Thus, it is not surprising that although 17␤-estradiol did not exert any effect on Kir channels (Nakajima et al., 1999; Tanabe et al., 1999) , it can activate ATP-sensitive K ϩ channels. Many agonists have been shown to trigger the opening of ATP-sensitive K ϩ channels, including adenosine, bradykinin, opioids, and free radicals (Downey and Cohen, 1997) . Estradiol increased adenosine levels, opioid sensitivity, bradykinin concentrations, and nitric oxide, which may increase the open-state probability of ATP-sensitive K ϩ channels as measured by patch-clamp technique (Downey and Cohen, 1997) . Multiple numbers of the triggers intensify the downstream signals to activate the two types of ATP-sensitive K ϩ channels. First, mit-K ATP channel activation was involved in the mechanism modulating estradiol-induced infarct size reduction demonstrated by the fact that infarct sizes increased by administering 5-hydroxydecanoate in the presence of estradiol. Because 5-hydroxydecanoate alone did not alter infarct size, the abrogation of infarct size limitation cannot be ascribed to a detrimental effect of this agent. Opening of mit-K ATP channels results in K ϩ influx in to the mitochondrial matrix (Sakamoto et al., 1998) . Mitochondrial membrane depolarization induced by K ϩ influx would lead to a reduction in the driving force responsible for Ca 2ϩ uptake and/or activation of Ca 2ϩ release (Holmuhamedov et al., 1999; Jovanovic et al., 1999) . Besides, mitochondrial Ca 2ϩ overload during ischemia-reperfusion can be reversed by mit-K ATP channel agonists (Holmuhamedov et al., 2001 ). The attenuated mitochondrial Ca 2ϩ overload has been closely correlated with the preservation of cell integrity. Thus, it suggests that the opening of mit-K ATP channels may have been associated with reduced infarct sizes by attenuated Ca 2ϩ overload. The result was consistent with previous finding (Liu et al., 1998) , showing that mit-K ATP channels, but not sar-K ATP channels, modulate cell viability.
Second, sar-K ATP channel activation was involved in the mechanism modulating estradiol-induced reduction of reperfusion arrhythmia demonstrated by the fact that fatal arrhythmias worsened after the administration of HMR 1098. Although the antiarrhythmic effects of sar-K ATP channel antagonists has been documented during ischemia, there were controversial in vivo data of the literature supporting either proarrhythmic or antiarrhythmic effects (Baczko et al., 1997; Rioufol et al., 1997; Kita et al., 1998; Wirth et al., 1999;  Table  4 ). Different agonists and antagonists including specific and nonspecific agents were used to assess anti-and pro-arrhythmic effects of ATP-sensitive K ϩ channels. Because of many other effects in nonspecific agents, it is difficult to compare these studies. For example, glibenclamide was able to prevent accumulation of free arachidonic acid released from the reperfused cell membrane (Picard et al., 1998) . Because accumulated free fatty acids can induce arrhythmias (Oliver and Opie, 1994) , an indirect antiarrhythmic action of glibenclamide cannot be excluded. Besides, prolonged ischemia results in much greater increases in intracellular calcium concentrations and produces triggered arrhythmias. Shortening of action potential duration by sar-K ATP channel agonists might diminish this type of arrhythmia by decreasing intracellular calcium concentrations. Furthermore, there are variable amounts of myocardial ATP-sensitive K ϩ channels in different species. The amount of sar-K ATP channels is expressed at high levels in rat and mouse (Inagaki et al., 1995) . The different amount of sar-K ATP channels explained, at least in part, why estradiol only produced an antiarrhythmic effect at 10-fold the physiological doses in rats (Li et al., 2000) , which contrasted with our finding in dogs at physiological doses. Taken together, different species, different specificity of drugs, and experimental models of different myocardial ischemic durations may explain the inconsistent data of roles of ATP-sensitive K ϩ channels in arrhythmias. There are differences in triggering mechanisms between ischemia-and reperfusion-induced arrhythmias. Arrhythmias occurring in response to acute ischemia are believed to be caused primarily by reentry, whereas arrhythmias occurring upon reperfusion may be caused by delay after depolarization (triggered activity) (Wilde and Janse, 1994) . sar-K ATP channel agonists have been shown to aggravate reentry-type arrhythmias but to inhibit triggered-type arrhythmias (Chi et al., 1990) . Our result showed that the sar-K ATP channel antagonist HMR 1098 exerts a proarrhythmic effect in the presence of estradiol. The proarrhythmic effect could not be due to hypoglycemia, vasoconstriction, or a reduction in coronary flow, which are common confounding factors in using sulfonylurea. Opening of sar-K ATP channels enhances the shortening of the action potential duration by accelerating repolarization, which would inhibit calcium entry into the cells (Jovanovic et al., 1999) . Because reperfusion arrhythmia may occur secondary to calcium overload (Li and Ferrier, 1992) , activation of sar-K ATP channels may protect against arrhythmias by attenuating calcium overload during reperfusion.
Estradiol has been shown to prolong action potential duration (Tanabe et al., 1999) , which was in contrast to the notion that activation of estradiol-induced sar-K ATP channels enhances the shortening of the action potential duration. The repolarization phase of the action potential is formed by several ionic channels, including inward Ca 2ϩ current, transient outward K ϩ current, and delayed outward K ϩ current, which overlap each other with similar time courses (Nakajima et al., 1999) . Previous studies have shown that estradiol inhibited inward Ca 2ϩ current, which shortens the action potential duration in guinea pig ventricular muscles (Nakajima et al., 1999) . However, the inhibition of estradiol-induced transient outward K ϩ current (Berger et al., 1997) and delayed outward K ϩ current (Tanabe et al., 1999) prolongs the action potential duration in rat hearts. Our result show that estradiol activates sar-K ATP channels, which shortens the action potential duration. However, because mul- tiple ion channel responses occur concomitantly, it is not possible to elucidate the specific contributions of changes in coupling to action potential duration. Thus, our result may not necessarily indicate that estrogen exhibits shortening of action potential duration.
Other Mechanisms. Although the present study suggests that the mechanisms of estrogen-induced antiarrhythmia may be related to opening of ATP-sensitive K ϩ channels, other potential mechanisms need to be studied. 17␤-Estradiol may reduce arrhythmia by attenuating catecholamine-induced injury. Aupetit et al. (1998) showed that the adrenoceptor blockade protects against reperfusion arrhythmia after prolonged ischemia. Myocardial infarction can alter the control of sympathetic tone, which has been linked to an increased extent of infarction and sudden cardiac death after myocardial infarction (Aupetit et al., 1998 ). It appears that modification of autonomic tone of estrogen may have an impact on electrical stability. However, HMR 1098 blocked the antiarrhythmic effects of estrogen, arguing against a significant role of other factors that might be altered by estrogen. Therefore, we believe that other mechanisms mediated by estrogen would not be a critical factor to attenuate fatal reperfusion arrhythmia.
Conclusions
This study demonstrates that estrogen at physiological concentrations effectively limits infarct sizes and diminishes fatal reperfusion-induced ventricular arrhythmias by different ATP-sensitive K ϩ channels for a nongenomic mechanism in the canine heart. The infarct size-limiting effect of estrogen was abolished by 5-hydroxydecanoate, suggesting that the effects may result from activation of the mit-K ATP channels. The antiarrhythmic effect of estrogen during reperfusion was associated with the activation of sar-K ATP channels because estrogen-mediated antiarrhythmic effect was inhibited by the blocker of sar-K ATP channels, HMR 1098.
